These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 34079441)

  • 1. Function and Regulation of ALDH1A1-Positive Nigrostriatal Dopaminergic Neurons in Motor Control and Parkinson's Disease.
    Carmichael K; Evans RC; Lopez E; Sun L; Kumar M; Ding J; Khaliq ZM; Cai H
    Front Neural Circuits; 2021; 15():644776. PubMed ID: 34079441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct Connectivity and Functionality of Aldehyde Dehydrogenase 1a1-Positive Nigrostriatal Dopaminergic Neurons in Motor Learning.
    Wu J; Kung J; Dong J; Chang L; Xie C; Habib A; Hawes S; Yang N; Chen V; Liu Z; Evans R; Liang B; Sun L; Ding J; Yu J; Saez-Atienzar S; Tang B; Khaliq Z; Lin DT; Le W; Cai H
    Cell Rep; 2019 Jul; 28(5):1167-1181.e7. PubMed ID: 31365862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation.
    Liu G; Yu J; Ding J; Xie C; Sun L; Rudenko I; Zheng W; Sastry N; Luo J; Rudow G; Troncoso JC; Cai H
    J Clin Invest; 2014 Jul; 124(7):3032-46. PubMed ID: 24865427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional significance of aldehyde dehydrogenase ALDH1A1 to the nigrostriatal dopamine system.
    Anderson DW; Schray RC; Duester G; Schneider JS
    Brain Res; 2011 Aug; 1408():81-7. PubMed ID: 21784415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in the nigrostriatal system following conditional inactivation of α-synuclein in neurons of adult and aging mice.
    Ninkina N; Tarasova TV; Chaprov KD; Roman AY; Kukharsky MS; Kolik LG; Ovchinnikov R; Ustyugov AA; Durnev AD; Buchman VL
    Neurobiol Aging; 2020 Jul; 91():76-87. PubMed ID: 32224067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldehyde dehydrogenase 1-positive nigrostriatal dopaminergic fibers exhibit distinct projection pattern and dopamine release dynamics at mouse dorsal striatum.
    Sgobio C; Wu J; Zheng W; Chen X; Pan J; Salinas AG; Davis MI; Lovinger DM; Cai H
    Sci Rep; 2017 Jul; 7(1):5283. PubMed ID: 28706191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson's disease.
    Stott SRW; Barker RA
    Eur J Neurosci; 2014 Mar; 39(6):1042-1056. PubMed ID: 24372914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
    Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
    Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.
    Kordower JH; Olanow CW; Dodiya HB; Chu Y; Beach TG; Adler CH; Halliday GM; Bartus RT
    Brain; 2013 Aug; 136(Pt 8):2419-31. PubMed ID: 23884810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conditional deletion of Ndufs4 in dopaminergic neurons promotes Parkinson's disease-like non-motor symptoms without loss of dopamine neurons.
    Choi WS; Kim HW; Tronche F; Palmiter RD; Storm DR; Xia Z
    Sci Rep; 2017 Mar; 7():44989. PubMed ID: 28327638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons.
    Dragicevic E; Poetschke C; Duda J; Schlaudraff F; Lammel S; Schiemann J; Fauler M; Hetzel A; Watanabe M; Lujan R; Malenka RC; Striessnig J; Liss B
    Brain; 2014 Aug; 137(Pt 8):2287-302. PubMed ID: 24934288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue engineered nigrostriatal pathway for treatment of Parkinson's disease.
    Struzyna LA; Browne KD; Brodnik ZD; Burrell JC; Harris JP; Chen HI; Wolf JA; Panzer KV; Lim J; Duda JE; España RA; Cullen DK
    J Tissue Eng Regen Med; 2018 Jul; 12(7):1702-1716. PubMed ID: 29766664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease.
    Nordströma U; Beauvais G; Ghosh A; Pulikkaparambil Sasidharan BC; Lundblad M; Fuchs J; Joshi RL; Lipton JW; Roholt A; Medicetty S; Feinstein TN; Steiner JA; Escobar Galvis ML; Prochiantz A; Brundin P
    Neurobiol Dis; 2015 Jan; 73():70-82. PubMed ID: 25281317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling of the Progressive Degradation of the Nigrostriatal Dopaminergic System in Mice to Study the Mechanisms of Neurodegeneration and Neuroplasticity in Parkinson's Disease.
    Kolacheva A; Bannikova A; Pavlova E; Bogdanov V; Ugrumov M
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldehyde Dehydrogenase 1 making molecular inroads into the differential vulnerability of nigrostriatal dopaminergic neuron subtypes in Parkinson's disease.
    Cai H; Liu G; Sun L; Ding J
    Transl Neurodegener; 2014; 3():27. PubMed ID: 25705376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.
    Korecka JA; Moloney EB; Eggers R; Hobo B; Scheffer S; Ras-Verloop N; Pasterkamp RJ; Swaab DF; Smit AB; van Kesteren RE; Bossers K; Verhaagen J
    J Neurosci; 2017 Sep; 37(39):9361-9379. PubMed ID: 28842419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ASL expression in ALDH1A1
    Lerner S; Eilam R; Adler L; Baruteau J; Kreiser T; Tsoory M; Brandis A; Mehlman T; Ryten M; Botia JA; Ruiz SG; Garcia AC; Dionisi-Vici C; Ranucci G; Spada M; Mazkereth R; McCarter R; Izem R; Balmat TJ; Richesson R; ; Gazit E; Nagamani SCS; Erez A
    Hum Genet; 2021 Oct; 140(10):1471-1485. PubMed ID: 34417872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.
    Biondetti E; Santin MD; Valabrègue R; Mangone G; Gaurav R; Pyatigorskaya N; Hutchison M; Yahia-Cherif L; Villain N; Habert MO; Arnulf I; Leu-Semenescu S; Dodet P; Vila M; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2021 Nov; 144(10):3114-3125. PubMed ID: 33978742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
    Sloan M; Alegre-Abarrategui J; Potgieter D; Kaufmann AK; Exley R; Deltheil T; Threlfell S; Connor-Robson N; Brimblecombe K; Wallings R; Cioroch M; Bannerman DM; Bolam JP; Magill PJ; Cragg SJ; Dodson PD; Wade-Martins R
    Hum Mol Genet; 2016 Mar; 25(5):951-63. PubMed ID: 26744332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sox6 expression distinguishes dorsally and ventrally biased dopamine neurons in the substantia nigra with distinctive properties and embryonic origins.
    Pereira Luppi M; Azcorra M; Caronia-Brown G; Poulin JF; Gaertner Z; Gatica S; Moreno-Ramos OA; Nouri N; Dubois M; Ma YC; Ramakrishnan C; Fenno L; Kim YS; Deisseroth K; Cicchetti F; Dombeck DA; Awatramani R
    Cell Rep; 2021 Nov; 37(6):109975. PubMed ID: 34758317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.